Impact of the 17-Gene Genomic Prostate Score Assay on Low Risk Prostate Cancer Patients in the Veterans Health Care Administration

Abstract

62% pursued AS. Use of AS varied across VAMCs (range:31%-84%). AS increased with age, and decreased with higher GS and NCCN risk group. Characteristics were similar among the 97 Veterans prospectively enrolled, including NCCN risk (VL: 24%, L: 38%, INT: 38%). A wide range of GPS results were observed (4-48).The GPS provided a refined risk group in 5% of VL, 27% of L, and 9% of INT. ConClusions: Both groups of patients had characteristics representative of low risk PCa in the VA. Chart review confirmed variation in use of AS. Analysis of 97 tested Veterans showed refined risk estimates after GPS. Results presented at the meeting will demonstrate the ability of the GPS assay to identify men with low risk PCa for AS or immediate therapy using individualized biological information.